Home Trials Current Trials

ASTN Current Trials

TEMPO-2: TNK-tPA for Minor Ischemic Stroke with Proven Acute Symptomatic Occlusion Trial 2

E-mail Print PDF

Lead PI: Dr Shelagh B Coutts

Status: Recruiting

No. of Patients Currently Recruited: 139                                 No. of Patients Required: 1274

TEMPO-2 is examining the role of thrombolysis with low-dose (0.25mg/kg) tenecteplase for patients with minor stroke (NIHSS 0-5) and proven intracranial occlusion (defined by CTA or CTP) in reducing disability at 90 days after stroke onset. The study will enrol up to 1274 patients in Canada, Europe and Australia.

Trial URL: 

https://clinicaltrials.gov/ct2/show/NCT02398656?term=TEMPO&cond=stroke&rank=1

NCT02398656

Last Updated ( Thursday, 25 January 2018 16:05 )
 

ESCAPE NA-1: Extension of Stroke Care by Added neuroProtection to Endovascular treatment

E-mail Print PDF

Lead PI: Professor Michael D Hill and Dr Mayank Goyal

Status: Recruiting

No. of Patients Currently Recruited: 143                                No. of Patients Required: 1120

ESCAPE-NA1 is examining the rapid addition of single dose NA-1 to the treatment of acute ischemic stroke patients with large vessel occlusion undergoing endovascular thrombectomy.  Patients are randomized 1:1 to study drug (active drug or saline placebo) and then followed for 90 days.  The primary outcome is disability measured on the modified Rankin Scale at 90 days.  Up to 1120 patients will be recruited from centres in Canada, US, Europe/UK, South Korea and Australia.

Trial URL:

www.escapena1.ca

https://clinicaltrials.gov/ct2/show/NCT02930018?cond=escape-na1&rank=1

NCT02930018

Last Updated ( Tuesday, 23 January 2018 13:17 )
 

TEXAIS: A Multicentre, randomised controlled Trial of Exenatide versus standard care in Acute Ischemic Stroke

E-mail Print PDF

Lead PI: Professor Chris Bladin

Status: Site Selection

No. of Patients Currently Recruited: 0                               No. of Patients Required: 528

Phase 2, multicentre, prospective, randomised, open label, blinded end-point (PROBE) trial with pre-planned adaptive sample size re-estimation. 10 sites anticipated to randomise 528 (1:1 ratio) patients by 2019. Primary Hypothesis: Treatment with short acting Exenatide (Byetta) in patients with acute ischaemic stroke will improve neurological outcome as measured by >8 point improvement in NIHSS stroke disability score (or NIHSS 0-1) at 7 days.

Trial URL:

https://clinicaltrials.gov/ct2/show/NCT03287076

Last Updated ( Wednesday, 10 January 2018 13:00 )
 

TASTE: Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial

E-mail Print PDF

Lead PI: Professor Mark Parsons

Status: Recruiting

No. of Patients Currently Recruited: 197                                No. of Patients Required: 400

Multicentre, prospective, randomised open-label blinded endpoint (PROBE) phase III study including acute stroke patients with hemispheric ischaemia who have penumbra on perfusion CT (CTP) or MRI within 4.5 hours of stroke onset. The primary objective of this study is to test the hypothesis that patients with acute hemispheric ischaemic stroke who have a penumbra on perfusion CT or MRI within 4.5hrs of symptom onset will have less disability at 3 months when treated with IV TNK compared to IV tPA.

Trial URL:

http://clinicaltrials.gov.show/NCT01472926 
Last Updated ( Wednesday, 10 January 2018 13:01 )
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  Next 
  •  End 
  • »
Page 1 of 4


ASTN Latest news

Top Views